The Board  oversees the work of SIOPE and provides guidance in administering the organisation. It meets approximately every month, to discuss the priorities and issues at stake and agree on a joint approach to problem solving.  More specifically, the role of the SIOPE Board is to:

  • Provide strategic advice on paediatric oncology in Europe;
  • Define priorities and targets of the organisation;
  • Review SIOPE financial management and scrutiny of annual accounts;
  • Provide expert input on scientific policy and management issues.

The Board is led by the President and is composed of the President-Elect or Past-President (depending on the term), the Treasurer, the Chief Executive Officer, the SIOPE Clinical Research Council Chairs and a certain number of other Board Members (currently 11), each with expertise in a specific field.

Board members are either elected by the General Assembly or appointed by the Board – for their particular expertise – for a three-year term, renewable for only one consecutive term.  The work of the Board is supported by the SIOPE team.


Professor Pamela Kearns

SIOPE President (UK), University of Birmingham, Cancer Research Clinical Trials Unit, United Kingdom

Stefan Bielack

(DE), Olgahospital, Klinikum Stuttgart, Germany

Gilles Vassal

(FR), Institut Gustave Roussy, Villejiuf, France

Tom Boterberg

(BE), University of Ghent, Ghent, Belgium

François Doz

(FR), Institut Curie, Paris, France

Lars Hjorth

(SE), University Hospital Lund, Sweden

Ruth Ladenstein

(AT), St. Anna’s Children’s Hospital, Vienna, Austria

Carmelo Rizzari

(IT), University of Milano-Bicocca, Italy

Tomasz Szczepanski

(PL), Dept. of Paediatric Haematology & Oncology, Zabrze, Poland

Reineke Schoot

(NL), Prinses Máxima Center for Pediatric Oncology, Utrecht, Netherlands

Andishe Attarbaschi

(AT), St. Anna Children’s Hospital, Vienna, Austria